

Cannovum AG enters into supply agreement for medical cannabis with WEECO

Berlin, 07.12.2022 – Cannovum AG, the first German fully licensed cannabis company on the stock exchange, enters into a partnership with WEECO Pharma GmbH. As of today, Cannovum will include WEECO's products in its portfolio, taking another important step towards becoming a full-service cannabis provider.

"Through this cooperation, we can even better support physicians and pharmacists in finding the right treatment for their patients," says Pia Marten, CEO of Cannovum AG. **"We are expanding our product portfolio to enable them to customize therapy according to their needs. By entering into this agreement with WEECO, we are confident that we can offer high-quality medicines to ensure that every patient receives the best therapy."**

"WEECO stands for uncompromising quality. In collaboration with leading international producers of medical craft cannabis, we provide an exclusive supply chain infrastructure for the European cannabis ecosystem," says Rene Zix, WEECO Head of Sales.

Based in Hildesheim, Germany, WEECO Pharma GmbH was founded in 2019 and is an independent pharmaceutical wholesale company. In addition to GDP certification (Good Distribution Practice), WEECO Pharma holds all necessary approvals and licenses to distribute medical cannabis products in Germany and worldwide. Through close cooperation with international manufacturers and WEECO Aps. an individual product range with the highest possible quality can be offered to the customer.

About Cannovum:

Cannovum AG is the first German fully licensed cannabis company listed on the stock exchange. The shares are traded on the stock exchanges in Düsseldorf, Munich, Berlin, Hamburg and gettex. Through its subsidiary Cannovum Health eG, it is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the importation of high-quality cannabinoid precursors, medical-scientific education and nationwide distribution for simplified and equitable access to cannabis-based therapies.

For more information, visit www.cannovum.de

Contact:

Klaus Madzia, IR & PR, Cannovum AG

Phone +49 30 3982 163 62, klaus.madzia@cannovum.com

Cannovum AG
Rheinsberger Str. 76/77
10115 Berlin
T: 030/3982163 60
E: info@cannovum.com
W: www.cannovum.de
ISIN: DE000A2LQU21
WKN: A2LQU2
Börsen: Düsseldorf, Berlin, Hamburg, München, gettex